# NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

> **NCT01098266** · PHASE3 · COMPLETED · sponsor: **AGC Biologics S.p.A.** · enrollment: 400 (actual)

## Conditions studied

- Malignant Pleural Mesothelioma

## Interventions

- **DRUG:** NGR-hTNF plus Best Investigator's Choice (BIC)
- **DRUG:** Placebo plus Best Investigator's Choice (BIC)

## Key facts

- **NCT ID:** NCT01098266
- **Lead sponsor:** AGC Biologics S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-12
- **Primary completion:** 2014-04-29
- **Final completion:** 2017-12
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2019-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01098266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01098266, "NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01098266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*